A new study from the Tufts Center for the Study of Drug Development indicates that artificial intelligence can significantly reduce the costs and timelines associated with clinical trials for cancer treatments. The analysis suggests AI-powered tools could shorten trial durations by approximately 10 weeks and save up to $5.6 million in operating costs for late-stage trials. These efficiencies are projected to become standard in clinical trials within three to five years, potentially lowering drug failure rates and freeing up resources for further research. AI
IMPACT AI integration in clinical trials promises significant cost savings and accelerated timelines, potentially improving drug development success rates.
RANK_REASON The cluster reports on findings from a new study quantifying the impact of AI on clinical trials. [lever_c_demoted from research: ic=1 ai=0.7]
- Artificial intelligence
- cancer treatments
- clinical trial
- Medable
- Research Study
- Tufts Center for the Study of Drug Development
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
